Clinical trial
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral…
NCT00007345 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00007345 |
|---|---|
| Title | Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma |
| Official title | Phase II Trial of Depsipeptide in Patients With Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T Cell Lymphoma, Peripheral T Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Romidepsin |
| Enrollment | 131 |
| Start date | Mar 8, 2001 |
| Primary completion | Jan 26, 2015 |
| Completion | Jul 27, 2015 |
| First posted | Dec 18, 2000 |
| Last update posted | May 16, 2017 |
| Countries | Australia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: